HUP0401805A2 - Compounds suitable for treating pulmonary diseases - Google Patents

Compounds suitable for treating pulmonary diseases

Info

Publication number
HUP0401805A2
HUP0401805A2 HU0401805A HUP0401805A HUP0401805A2 HU P0401805 A2 HUP0401805 A2 HU P0401805A2 HU 0401805 A HU0401805 A HU 0401805A HU P0401805 A HUP0401805 A HU P0401805A HU P0401805 A2 HUP0401805 A2 HU P0401805A2
Authority
HU
Hungary
Prior art keywords
compounds suitable
pulmonary diseases
treating pulmonary
receptor antagonists
adenosine receptor
Prior art date
Application number
HU0401805A
Other languages
Hungarian (hu)
Inventor
Glenn J. Smits
Francis G. Spinale
Original Assignee
Biogen Idec Ma Inc.
Musc Foundation For Research Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc., Musc Foundation For Research Development filed Critical Biogen Idec Ma Inc.
Publication of HUP0401805A2 publication Critical patent/HUP0401805A2/en
Publication of HUP0401805A3 publication Critical patent/HUP0401805A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A találmány tárgya A1 adenozin receptor antagonisták alkalmazásáravonatkozik pulmonális érszűkület csökkentésére vagy pulmonálishemodinamika javítására. A találmány szerinti A1 adenozin receptorantagonisták adagolását előnyösen gyógyszerkészítmény formájábanvégzik, amely gyógyszerkészítmény az A1 adenozin receptor antagonistákhatásos mennyiségét és gyógyszerészetileg elfogadható hordozót vagyhordozókat tartalmaz. ÓThe subject of the invention relates to the use of A1 adenosine receptor antagonists to reduce pulmonary vasoconstriction or improve pulmonary hemodynamics. The A1 adenosine receptor antagonists according to the invention are preferably administered in the form of a pharmaceutical preparation, which pharmaceutical preparation contains an effective amount of A1 adenosine receptor antagonists and a pharmaceutically acceptable carrier or carriers. HE

HU0401805A 2001-09-06 2002-09-06 Compounds suitable for treating pulmonary diseases HUP0401805A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31790801P 2001-09-06 2001-09-06
PCT/US2002/028580 WO2003022284A1 (en) 2001-09-06 2002-09-06 Methods of treating pulmonary disease

Publications (2)

Publication Number Publication Date
HUP0401805A2 true HUP0401805A2 (en) 2004-12-28
HUP0401805A3 HUP0401805A3 (en) 2007-05-02

Family

ID=23235775

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401805A HUP0401805A3 (en) 2001-09-06 2002-09-06 Compounds suitable for treating pulmonary diseases

Country Status (20)

Country Link
US (1) US20040259889A1 (en)
EP (1) EP1429775A4 (en)
JP (2) JP4388373B2 (en)
KR (1) KR100979738B1 (en)
CN (1) CN1564688A (en)
AU (1) AU2002341618B2 (en)
BR (1) BR0212329A (en)
CA (1) CA2459533A1 (en)
EA (1) EA014684B1 (en)
GE (1) GEP20074132B (en)
HU (1) HUP0401805A3 (en)
IL (1) IL160715A0 (en)
IS (1) IS7163A (en)
MX (1) MXPA04002135A (en)
NZ (1) NZ532083A (en)
PL (1) PL368935A1 (en)
UA (1) UA80258C2 (en)
WO (1) WO2003022284A1 (en)
YU (1) YU20104A (en)
ZA (1) ZA200401765B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS107404A (en) * 2002-06-12 2007-02-05 Biogen Idec Ma Inc., Method of treating ischemia perefusion injury using adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
EP1620107A1 (en) * 2003-04-25 2006-02-01 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
JP4859666B2 (en) * 2003-06-06 2012-01-25 エンダセア， インコーポレイテッド A1 adenosine receptor antagonist
CN101420958A (en) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 Throw altogether and adenosine A 1Receptor antagonist and anticonvulsant
WO2007149366A1 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
KR20090025262A (en) 2006-06-23 2009-03-10 인사이트 코포레이션 Purinone derivatives as hm74a agonists
MX2009000170A (en) 2006-06-23 2009-01-23 Incyte Corp Purinone derivatives as hm74a agonists.
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
EP2217233B1 (en) * 2007-10-26 2018-08-08 New York University School of Medicine Methods and compositions for treating hepatic diseases
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
US20100063071A1 (en) * 2008-06-13 2010-03-11 Kiesman William F Therapeutic compositions and related methods of use
JP2013533882A (en) * 2010-06-30 2013-08-29 ギリアード サイエンシーズ， インコーポレイテッド Use of A2B adenosine receptor antagonists to treat pulmonary hypertension
SG11201506800YA (en) * 2013-03-14 2015-09-29 Bristol Myers Squibb Co Bicyclo [2.2.2] acid gpr120 modulators
SG11202006435XA (en) 2018-01-04 2020-08-28 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
TW252044B (en) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
ATE226583T1 (en) * 1996-06-07 2002-11-15 Hoechst Ag USE OF THEOPHYLLINE DERIVATIVES FOR THE TREATMENT AND PROPYLAXIS OF SHOCK CONDITIONS, NEW XANTHINE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
EP1044003A4 (en) * 1998-01-09 2000-12-27 Univ Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
SI1230243T1 (en) * 1999-11-12 2009-08-31 Biogen Idec Inc Poycyloalkylpurines as adenosine receptor antagonists
ATE335489T1 (en) * 1999-12-02 2006-09-15 Osi Pharm Inc ADENOSINE A3, A2A AND A3 RECEPTORS SPECIFIC COMPOUNDS AND THEIR USES

Also Published As

Publication number Publication date
KR100979738B1 (en) 2010-09-09
MXPA04002135A (en) 2005-03-07
WO2003022284A1 (en) 2003-03-20
EP1429775A1 (en) 2004-06-23
US20040259889A1 (en) 2004-12-23
IL160715A0 (en) 2004-08-31
JP4388373B2 (en) 2009-12-24
AU2002341618B2 (en) 2008-06-26
UA80258C2 (en) 2007-09-10
JP2005501915A (en) 2005-01-20
BR0212329A (en) 2004-09-21
IS7163A (en) 2004-02-26
EA014684B1 (en) 2010-12-30
CA2459533A1 (en) 2003-03-20
JP2009209156A (en) 2009-09-17
GEP20074132B (en) 2007-06-25
ZA200401765B (en) 2005-04-05
PL368935A1 (en) 2005-04-04
KR20040040457A (en) 2004-05-12
EP1429775A4 (en) 2007-04-11
NZ532083A (en) 2005-10-28
HUP0401805A3 (en) 2007-05-02
CN1564688A (en) 2005-01-12
EA200400399A1 (en) 2004-08-26
YU20104A (en) 2006-08-17

Similar Documents

Publication Publication Date Title
HUP0401805A2 (en) Compounds suitable for treating pulmonary diseases
NZ522326A (en) Adenosine A2A receptor antagonists
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
HUP0203870A2 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
EA200601160A1 (en) 2,6-BISGETEROARIL-4-AMINOPYRIMIDINES AS ANTAGONISTS OF ADENOSIN RECEPTORS
ATE468332T1 (en) PHENYL-(4-(3-PHENYL-1H-PYRAZOLE-4-YL)-PYRIMIDINE- - YI)AMINE DERIVATIVES
HUP0003386A2 (en) Use of crf antagonists for the preparation of pharmaceutical compositions treating depression, cardiovascular diseases
MY138352A (en) Benzothiazole derivatives
DOP2002000429A (en) IMIDAZOTRIAZINAS
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2007075572A3 (en) Orally active purine-based inhibitors of heat shock protein 90
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
SE0102440D0 (en) New compound
MXPA03010054A (en) Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents.
NO20031410L (en) Use of distamycin derivatives for the manufacture of drugs
HUP0401042A2 (en) Pharmaceutical compositions suitable for treating primary insomnia
ATE429435T1 (en) 7H-PYRROLOPYRIMIDINE DERIVATIVES
WO2002069944A3 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
HUP0303329A2 (en) New phenylpiperzines
HUP0301334A2 (en) Combined compositions against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolited
HUP0300686A2 (en) Pharmaceutical composition containing non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
HUP0401696A2 (en) Medicinal compositions containing angiotensin ii receptor antagonist

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees